Key result
AT1R activation drives cardiac hypertrophy, while AT2R and MasR signaling may prevent heart failure.
Why the study?
Heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, prompting a review of the roles of AT1R, AT2R, and MasR in acute and chronic hypertrophy.
Developing activators for AT2R and MasR may offer novel therapeutic strategies for treating heart failure by preventing maladaptive cardiac hypertrophy.
May support AT2R/MasR agonism to counter maladaptive hypertrophy; leaves open clinical efficacy pending prospective trials.
Angiotensin II (Ang II) is formed by the action of angiotensin-converting enzyme (ACE) in the renin-angiotensin system. This hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro- and antihypertrophic Ang II receptors (AT1R and AT2R). Ang II is also metabolized by ACE 2 to Ang-(1-7), which elicits the activation of Mas receptors (MasR) for inducing antihypertrophic actions. Since heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, we have reviewed the existing literature to gain some information regarding the roles of AT1R, AT2R, and MasR in both acute and chronic conditions of cardiac hypertrophy. It appears that the activation of AT1R may be involved in the development of adaptive and maladaptive cardiac hypertrophy as well as subsequent heart failure because both ACE inhibitors and AT1R antagonists exert beneficial effects. On the other hand, the activation of both AT2R and MasR may prevent the occurrence of maladaptive cardiac hypertrophy and delay the progression of heart failure, and thus therapy with different activators of these antihypertrophic receptors under chronic pathological stages may prove beneficial. Accordingly, it is suggested that a great deal of effort should be made to develop appropriate activators of both AT2R and MasR for the treatment of heart failure subjects.
No takes yet. Share an insight, caveat, or question.
Bhullar et al. (2023) conducted a review in Cardiac hypertrophy and heart failure. Angiotensin receptor modulators (AT1R antagonists, AT2R and MasR activators) was evaluated. Activation of AT1R is involved in the development of adaptive and maladaptive cardiac hypertrophy, whereas activation of AT2R and MasR may prevent maladaptive hypertrophy and delay heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Heart failureMore from Canadian Journal of Physiology and Pharmacology